Molbio Diagnostics has raised ₹281.5 crore from anchor investors, confirming robust institutional interest ahead of its initial public offering.
The subscription for the IPO is scheduled to open on August 10, following the company's earlier announcement of a price band between ₹768 and ₹807 per equity share.
The offering structure includes a fresh issue of shares worth up to ₹200 crore, alongside an offer for sale (OFS) of up to 91.66 lakh equity shares by existing shareholders.
The full subscription by anchor investors suggests that institutional buyers are positioning themselves early in the deal, potentially reducing the risk of under-subscription in the retail and QIB (Qualified Institutional Buyers) portions of the book.
As a key player in India's point-of-care diagnostics market, Molbio's move to list comes amid heightened activity in the healthcare IPO space.
The strong anchor response validates the company's valuation and market position, providing a benchmark for other diagnostic firms considering public listings in the near term.